lacosamide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 59 Diseases   24 Trials   24 Trials   1996 News 


12345678910111213...2526»
  • ||||||||||  lacosamide / Generic mfg., flecainide / Generic mfg.
    Journal:  Reversibility of a (Pubmed Central) -  Dec 10, 2024   
    We observed that early use of lacosamide, even in young infants, demonstrated good efficacy and safety. The case of a
  • ||||||||||  Understanding the Natural History of cyfip2-related Epilepsy (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2561;    
    Patients with CYFIP2-related DEE have developmental delay, epilepsy with multiple seizure types, and a hyperkinetic movement disorder. Ours is the only reported case of substantial improvement with timely treatment following initial seizure onset and prior to epileptic spasms.
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma, lamotrigine liquid oral suspension / OWP Pharma
    The Use of Ketogenic Diet During Pregnancy to Treat NORSE (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2532;    
    KD therapy is one of a paucity of potentially effective treatments for NORSE, but in the setting of pregnancy therapeutic ketosis may not be achievable due to minimum protein requirements. Because other NORSE treatments also have teratogenic potential, a multidisciplinary discussion of the risks and benefits of all treatments, including possible short term protein restriction to maximize KD therapy, should be initiated early with family.
  • ||||||||||  lacosamide / Generic mfg., oxcarbazepine / Generic mfg.
    Stereotyped Post-ictal Texting Behavior as a Potential Biomarker in a Case of Drug-resistant Focal Epilepsy (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2479;    
    This behavior appears to be a reliable marker of the patient's ongoing focal seizures and may serve as a useful biomarker to track her response to treatment. A literature review demonstrates that texting behavior has never been reported in relation to ictal or post-ictal processes.
  • ||||||||||  Seizures in the Leukodystrophies Analyzed by Diagnosis and Pathogenetic Mechanism (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2443;    
    Patients with an astrocytopathy were more affected by seizures overall, and more often went on to develop focal epilepsy than patients with a myelinopathy. Lacosamide, levetiracetam, and zonisamide demonstrated the highest overall response rates.
  • ||||||||||  Prescribing Trends of Antiseizure Medications in Veterans with Epilepsy (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2373;    
    Data analysis suggests a transition towards prescribing newer ASMs. With the increase in number of female Veterans and the risk of teratogenesis with valproate, phenytoin and topiramate ECoE sites are playing an important role in educating patients and guiding the optimal treatment factoring in gender, epilepsy syndrome and age to improve patient care outcomes.
  • ||||||||||  lacosamide / Generic mfg., pregabalin / Generic mfg., brivaracetam / Generic mfg.
    Monitoring Anti-seizure Medication Efficacy with Sub-scalp EEG (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2296;    
    P
    Large deviations in expected residual values indicate a change in seizure rate due ASM. A non-sustained change in residuals is an early indicator of ineffective ASM, flagging the need to try another therapy.
  • ||||||||||  lacosamide / Generic mfg.
    Lennox-gastaut Lacosamide Efficacy: Case Report (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2261;    
    Although there is better tolerability of clobazam (CLB) compared to short acting BZDs, its effect in LGS specifically is poorly understood... Case: We have a 16 yo M with LGS who presented with acute repetitive generalized tonic seizures secondary to suboptimal medication adherence on dual regimen of levetiracetam (LEV) and lamotrigine (LTG)...He had poor response to initial abortive BZDs, fosphenytoin and VPA loads and was ultimately preemptively intubated and placed on a midazolam drip with escalating doses (to maximum of 20 mg/hr)...However, he remains at elevated risk for SUDEP and is undergoing surgical evaluation for Vagal Nerve Stimulator placement.
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma, Epidiolex (cannabidiol) / Jazz, Xcopri (cenobamate) / SK Bio
    Implementing an Interactive Dashboard to Evaluate Medication Side Effects in People Living with Epilepsy (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2213;    
    Commonly used drugs were levetiracetam (Keppra, Roweepra, Spritam), lamotrigine (Lamictal), and Lacosamide (Vimpat), while newer less frequently used drugs were cenobamate (Xcopri), cannabidiol (Epidiolex), and perampanel (Fycompa). This interactive dashboard can help screen PWEs to identify those with side effects to certain medications, which can differ by degree of seizure control; this could allow for more informed decision-making on balancing side effects and seizure control for future medication trials.
  • ||||||||||  lacosamide / Generic mfg., levetiracetam / Generic mfg.
    Ictal Asystole During Focal Impaired Awareness Seizures: A Case Report (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2192;    
    Ictal asystole has been managed thus far with antiepileptic medications and pacemakers to minimize morbidity. In terms of the significance of these findings, this case report demonstrates that patients with ictal asystole require close monitoring with both neurology and cardiology, and that guidelines for optimal medical management after pacemaker placement are needed to reduce seizure recurrence without exacerbating the risk of asystole.
  • ||||||||||  lacosamide / Generic mfg., phenytoin / Generic mfg.
    Electrophysiological Effects of Phenytoin and Lacosamide on SCN8-DEE (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2117;    
    Both phenytoin and lacosamide were effective in treating SCN8A-DEE. Due to the differences in the time-dependent effects on spike onset between these two antiseizure medications, phenytoin and lacosamide could be used as monotherapy or in combination therapy based on their distinct mechanisms of action.
  • ||||||||||  Xcopri (cenobamate) / SK Bio
    Adjunctive Cenobamate in Children and Adolescents  (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2033;    
    Significantly, we demonstrate this in the younger pediatric population, which has not previously been reported in the literature. Our findings support the administration of cenobamate in children and adolescents with focal, drug resistant epilepsy as adjunctive therapy alongside the use of more established ASMs, although with caution required regarding drug interactions.
  • ||||||||||  Xcopri (cenobamate) / SK Bio
    The Fruit Fly Drosophila Melanogaster as a Screening Tool for Antiseizure Medications (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1954;    
    These findings further demonstrate the usability of Drosophila for assaying drugs with antiseizure properties. Next, the same ASMs will be tested in another bang-sensitive mutant (paralyticbss1) that serves as a model for intractable epilepsy.
  • ||||||||||  Seizure Management in Creutzfeldt-jakob Disease (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1912;    
    Benzodiazepines showed some efficacy on EEG, with limited clinical benefit. Considering ASMs such as Clonazepam, Lorazepam, and probably try Clobazam as possible options.
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma, Xcopri (cenobamate) / SK Bio
    Leveraging EPIC Workbench Reporting to Create an Epilepsy Clinic Dashboard (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1777;    
    Our results reveal that between 2013 and 2023, (i) the population of patients that we serve has almost doubled in size, (ii) their seizure severity has increased and (iii) rates of valproate and topiramate use have remained constant in female patients of reproductive age. We design a "clinic dashboard" prototype that can seamlessly sort and identify patients by polytherapy burden and visit compliance.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI, Yescarta (axicabtagene ciloleucel) / Gilead
    Full Neurological Recovery in Icans-related Super-refractory Status Epilepticus (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1698;    
    IT methotrexate and hydrocortisone were initiated... Resolution of focal deficits, and seizures, as well as ASM cessation is possible in ICANS related SE when neuro-inflammation is stopped before structural damage is established.
  • ||||||||||  lacosamide / Generic mfg., levetiracetam / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    From Diagnosis to Recovery: Managing New Onset Refractory Seizures in a 51-year-old Female with Anti-gaba-b Receptor Encephalitis (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1697;    
    The patient's significant recovery and sustained seizure-free status demonstrate the efficacy of combining immunotherapy and antiseizure medications. Regular follow-up are crucial, especially given the finding that the maximum interval from encephalitis diagnosis to the discovery of a tumor was 28 months in a cohort.
  • ||||||||||  Effect of Ketogenic Diet Initiation Free Patients with Super Refractory Status Epilepticus Case Series (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1620;    
    Total VPA concentrations decreased while free VPA concentrations increased after KD initiation, potentially increasing the risk of AEs. Critical illness, hypoalbuminemia, uremia, and elevated free fatty acids (FFAs) can increase VPA FF, and this series suggests KD initiation also increases VPA FF and that free VPA concentrations should be monitored in patients initiated on KD.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    A Case of Focal Neurologic Deficits, Seizure, and Lateralized EEG Findings After ECT (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1444;    
    Post-ECT seizures and complications are an uncommon occurrence, with only few reports in the literature, and our case is unique with left LPDs and LRDA being seen on the EEG following the procedure. This case adds further information to the limited knowledge and reporting of post-ECT complications.
  • ||||||||||  Fintepla (low-dose fenfluramine) / UCB
    Reviving Fenfluramine: A New Hope for Pediatric Apneic Seizures in SMC1A Mutations (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1341;    
    This case study reaffirms FFA's potential as a seizure treatment in pediatric neurology, particularly for patients with SMC1A mutations with apneic seizure, and underlines the imperative for further investigative efforts in this subgroup. Furthermore, the drastic reduction in apneic seizure frequency in this patient emphasized FFA's specific potential in preventing long-term hypoxic brain injury.
  • ||||||||||  Do Physicians Use New Asms in Order of Approval? (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1093;    
    In addition, Brivaracetam was trialed ahead of ASMs in the early group most often, possibly due to its earlier release date and the fact that Epidiolex is not approved for focal epilepsy. The more recently approved ASMs were used before Perampanel and Eslicarbazepine more than 63% and 75% of the time, respectively, suggesting that clinicians had more optimism about the newer ASMs than these older ones.
  • ||||||||||  Xcopri (cenobamate) / SK Bio
    Cenobamate-associated Weight Loss (CENOBAWEIGHT Study) (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1007;    
    A comprehensive review at one center reveals that 12 out of 191 patients experienced weight loss of greater than 10% attributable to cenobamate, with most patients at a dose of at least 200mg. In our cohort, the effect was reversible with minor dose reduction.
  • ||||||||||  Kineret (anakinra) / SOBI
    A 16-year-old Girl with Recurrent Refractory Status Epilepticus Post Recovery from NORSE (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_842;    
    The patient's hospital course included severe complications, emphasizing the need for further research to better understand the mechanism and effective treatment strategy. The use of cytokine panels and genetic testing has potential to customize management, guide future research and therapeutic targets.